MANKIND PHARMA STOCK

Outperformance of private sector banks may continue for next one year: Sandip Sabharwal

The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.

Hot Stocks: Brokerage view on Tata Consumer, Varun Beverages and Mankind Pharma

Top brokerage firms like Motilal Oswal, Jefferies, and Morgan Stanley have issued buy ratings and targets for Mankind Pharma, Nykaa, Tata Consumer, and Varun Beverages.

Pankaj Pandey on 4 sectors that may outperform in near term

​But our overall sense is that one needs to sort of watch out for Budget plus the element of optimism. Although they have some head room in terms of higher RBI dividend plus, obviously there can be structural savings on the subsidy side especially related to fertilisers, so it remains to be seen how they sort of utilise.

Buy Mankind Pharma, target price Rs 2650: Motilal Oswal

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 89132.93 Crore) operating in Pharmaceuticals sector.

These 6 large-cap stocks showing RSI Trending Up on June 10

Block deals worth over Rs 7,640 crore this week. Chandrababu Naidu’s Heritage Foods, Adani Ports see top action

The week was an eventful one. Besides the general election results, D-Street saw some prominent block deals which included over three dozen companies from large, mid and smallcap segments. Shares worth Rs 7,640 crore were traded on screen, which included both buying and selling.

Mankind Pharma in race with PEs to buy BSV Group at possible valuation of Rs 13,000 crore

Warburg Pincus, ChrysCapital, TPG, Blackstone, EQT, Mankind Pharma, and Dr Reddy's Laboratories are competing to acquire BSV Group, a biopharma firm specializing in women's health and critical care products, indicating a trend of consolidation in the domestic pharma sector. Mankind, Dr. Reddy’s, and Blackstone have evaluated BSV at different times, including before Advent's acquisition.

Stocks with tailwinds called advantage India: 5 largecap stocks from 3 different sectors with an upside potential of upto 36 %

In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sentiment was very bullish. The only difference between then and now is that we have election results which are coming up. Surely a confirmation on 4th June that continuity in the policy making is a big factor. But there is another thing which long term investors need to look at before investing. Whether the company or the sector has an advantage due to India as a country. A well known example, which has been present for decades is that of the IT industry. India as a country is a factory of software engineers, and that is our strength. So when investing for the long term, look at sectors where we have some strong tailwinds due to our human capital.

Bullish on NALCO, IOC & SAIL; Honeywell to touch Rs 1 lakh in future: Sanjiv Bhasin

Sanjiv Bhasin of IIFL Securities predicts Honeywell Automation's share price is going to reach Rs 1 lakh, while he had bought it years ago for Rs 89. Strong market performances by Hindustan Aeronautics and Mahindra indicate stability amidst FII selling worries. Opportunities in PSUs like NALCO, IOC, and SAIL emerge in the current market scenario.

Sanjiv Bhasin on why Biocon is a Dark Horse play and Mankind a ‘Hold’

Sanjiv Bhasin says Mankind has been a revelation purely on the back of some of the launches which have been well accepted and their domestic business has actually been way ahead of most of the peers. There is margin on the upside given that it is enlarging its share., but the stock has already run up a lot. So he says it should be a 'hold' for now.

Stocks in news: M&M, Vodafone Idea, Biocon, Mankind Pharma, Dixon Tech

HDFC Life announced its highest-ever bonus of Rs 3,722 crore on participating plans. This bonus will benefit over 22.23 lakh policyholders.

Mankind Pharma Q4 Results: PAT zooms 62% YoY to Rs 477 crore, revenue jumps 19%

Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its board approved the raising of funds worth Rs 7,500 crore via the issuance of equity shares. For the full financial year, the consolidated PAT stood at Rs 1,942 crore as against Rs 1,310 crore reported in FY23.

Stocks in news: PFC, Mankind Pharma, Patanjali Foods, Bharti Airtel, Siemens, Cipla

Benchmark equities surged for the third consecutive day on Tuesday. PFC, Mankind Pharma, Patanjali Foods, Bharti Airtel, Siemens, and Cipla are in focus for news developments and quarterly results. RVNL, Dixon, and Titagarh will also announce their fourth quarter results today.

Bharti Airtel, IndiGo among 10 largecap stocks wherein FIIs raised stake in Q4

Foreign institutional investors (FIIs) are typically major corporations that invest in countries outside their home base. Based on StockEdge data, here are 10 large-cap stocks from the Nifty200 index where FIIs increased their stake in Q4:

12 stocks likely to enter MSCI index in May rejig, trigger $2 billion inflows. Paytm to exit

Paytm will be a high conviction exclusion, causing outflows of $77 million from India, the domestic brokerages' note said. Paytm's exclusion comes after a nearly 40% correction in the share price following RBI's ban on its Paytm Payments Bank. Meanwhile, Berger has yielded nearly 9% returns over 1 year.

MSCI May rejig to trigger $3.2 billion inflows into 17 stocks

MSCI will announce the changes in the constituents of the MSCI global standard indices on May 14, while the changes will take place on May 31.

CARE Ratings upgrades PNB Housing Finance's various instruments; here's why

The instruments in which the ratings have been revised upwards include long-term bank facilities, long-term/short-term bank facilities, bonds, long-term instruments, non-convertible debentures (NCDs), tier II bonds, fixed deposits and commercial papers.

Rs 16,600-cr worth block deals take place this week; Mankind Pharma, Shriram Finance see significant action

In the largecap segment, 15 companies witnessed significant block deals.

Share market update: Most active stocks of the day in terms of traded value

The NSE Nifty index closed 92.05 points down at 22004.7

Gainers & Losers: HDFC Life, IndiGo among top 5 stocks that moved most on Tuesday

Share market update: Most active stocks of the day in terms of total traded value

The NSE Nifty index was trading 58.1 points down at 22038.65

HDFC Bank, RIL drag Sensex 200 pts lower; Nifty below 22,100

The BSE Sensex was trading 240 points or 0.33% lower at 72,603. Nifty50 was trading at 22,045, down 51 points or 0.23% at around 9.18 am.

Mankind Pharma stock falls 3% as PE investors likely sell 1.3 crore shares

PE firm ChrysCapital's affiliate entity Beige Ltd was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares of Mankind Pharma at a price range of Rs 2,103.21 to Rs 2,214 per share.